CICLOSPORIN

Information current as at: 1 December 2021

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Ikervis®
Pharmaceutical company:
Seqirus (Australia) Pty Ltd
Condition/indication:
(therapeutic use)
  • Dry eye disease in patients with keratitis
PBAC Submission type:
New listing (Major Submission)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
March 2021 PBAC meeting
Opportunity for consumer comment:
Open 23/12/2020 and close 10/02/2021 (see PBS Website)
PBAC meeting:
Held on 10/03/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
22/04/2021
Lodgement of required documentation:
21/05/2021
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 24/06/2021
Status:
Finalised
Government processes:
Commenced on 09/07/2021
Medicine listed on the PBS:
01/10/2021 (see PBS schedule)

Case ID: a290

Page last updated: 31 October 2021

v0.9.16